Preclin Biosystems AG is a privately owned company founded in June 2008, which offers a comprehensive in vivo preclinical testing platform for the identification and validation of lead candidate therapeutics.

Its extensive range of chronic inflammatory and infectious disease models are run routinely in its core facility providing a ‘one stop shop’ for preclinical drug efficacy testing. Its parallel testing approach for in vivo assessment of lead candidates can provide an overall efficacy, side effect and target market analysis condensing the preclinical phase of drug development dramatically.

For more information, go to: